{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:29:31Z","timestamp":1786321771160,"version":"build-2736575974"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":83,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-AI166835"],"award-info":[{"award-number":["R01-AI166835"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI150305"],"award-info":[{"award-number":["R01 AI150305"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-026-01489-7","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:37:05Z","timestamp":1779212225000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Vaccination in individuals with Down syndrome: immune vulnerability, safety, efficacy and opportunities"],"prefix":"10.1038","volume":"11","author":[{"given":"Bernard","family":"Khor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi A.","family":"Spinazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Chelales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Baumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bulova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Chicoine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Borzutzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana M.","family":"El Sahly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin M.","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa D.","family":"Gans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"McCormick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Partridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Rubenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cate","family":"Speake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanita Valdes","family":"Camacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishore","family":"Vellody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"1489_CR1","doi-asserted-by":"publisher","first-page":"e2301","DOI":"10.1002\/bdr2.2301","volume":"116","author":"EB Stallings","year":"2024","unstructured":"Stallings, E. B. et al. National population-based estimates for major birth defects, 2016-2020. Birth Defects Res. 116, e2301 (2024).","journal-title":"Birth Defects Res."},{"key":"1489_CR2","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/ajmg.a.37001","volume":"167A","author":"G de Graaf","year":"2015","unstructured":"de Graaf, G., Buckley, F. & Skotko, B. G. Estimates of the live births, natural losses, and elective terminations with Down syndrome in the United States. Am. J. Med. Genet. A 167A, 756\u2013767 (2015).","journal-title":"Am. J. Med. Genet. A"},{"key":"1489_CR3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.1741-1130.2010.00249.x","volume":"7","author":"J Torr","year":"2010","unstructured":"Torr, J. et al. Aging in Down syndrome: morbidity and mortality. J. Policy Pract. Intellect. Disabil. 7, 70\u201381 (2010).","journal-title":"J. Policy Pract. Intellect. Disabil."},{"key":"1489_CR4","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/ajmg.a.35706","volume":"161a","author":"A Englund","year":"2013","unstructured":"Englund, A. et al. Changes in mortality and causes of death in the Swedish Down syndrome population. Am. J. Med. Genet. A 161a, 642\u2013649 (2013).","journal-title":"Am. J. Med. Genet. A"},{"key":"1489_CR5","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/j.1469-8749.2004.tb00483.x","volume":"46","author":"AH Bittles","year":"2004","unstructured":"Bittles, A. H. & Glasson, E. J. Clinical, social, and ethical implications of changing life expectancy in Down syndrome. Dev. Med. Child Neurol. 46, 282\u2013286 (2004).","journal-title":"Dev. Med. Child Neurol."},{"key":"1489_CR6","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1002\/ajmg.a.62355","volume":"185","author":"JM Blake","year":"2021","unstructured":"Blake, J. M. et al. Pneumonia and respiratory infection in Down syndrome: a 10-year cohort analysis of inpatient and outpatient encounters across the lifespan. Am. J. Med Genet A 185, 2878\u20132887 (2021).","journal-title":"Am. J. Med Genet A"},{"key":"1489_CR7","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41436-020-01004-w","volume":"23","author":"L Malle","year":"2021","unstructured":"Malle, L. et al. Individuals with Down syndrome hospitalized with COVID-19 have more severe disease. Genet. Med. 23, 576\u2013580 (2021).","journal-title":"Genet. Med."},{"key":"1489_CR8","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1046\/j.1440-1754.1999.00386.x","volume":"35","author":"JM Hilton","year":"1999","unstructured":"Hilton, J. M., Fitzgerald, D. A. & Cooper, D. M. Respiratory morbidity of hospitalized children with trisomy 21. J. Paediatr. Child Health 35, 383\u2013386 (1999).","journal-title":"J. Paediatr. Child Health"},{"key":"1489_CR9","doi-asserted-by":"publisher","first-page":"100947","DOI":"10.1016\/j.dhjo.2020.100947","volume":"13","author":"SD Landes","year":"2020","unstructured":"Landes, S. D., Stevens, J. D. & Turk, M. A. Cause of death in adults with Down syndrome in the United States. Disabil. Health J. 13, 100947 (2020).","journal-title":"Disabil. Health J."},{"key":"1489_CR10","doi-asserted-by":"publisher","first-page":"100769","DOI":"10.1016\/j.eclinm.2021.100769","volume":"33","author":"A H\u00fcls","year":"2021","unstructured":"H\u00fcls, A. et al. Medical vulnerability of individuals with Down syndrome to severe COVID-19-data from the Trisomy 21 Research Society and the UK ISARIC4C survey. EClinicalMedicine 33, 100769 (2021).","journal-title":"EClinicalMedicine"},{"key":"1489_CR11","doi-asserted-by":"crossref","unstructured":"Clift, A. K. et al. COVID-19 mortality risk in Down syndrome: results from a cohort study of 8 million adults. Ann. Intern. Med. 174, 572\u2013576 (2021).","DOI":"10.7326\/M20-4986"},{"key":"1489_CR12","doi-asserted-by":"publisher","first-page":"n1592","DOI":"10.1136\/bmj.n1592","volume":"374","author":"EJ Williamson","year":"2021","unstructured":"Williamson, E. J. et al. Risks of covid-19 hospital admission and death for people with learning disability: population based cohort study using the OpenSAFELY platform. Bmj 374, n1592 (2021).","journal-title":"Bmj"},{"key":"1489_CR13","doi-asserted-by":"publisher","first-page":"101174","DOI":"10.1016\/j.dhjo.2021.101174","volume":"15","author":"Y Lunsky","year":"2022","unstructured":"Lunsky, Y. et al. COVID-19 positivity rates, hospitalizations and mortality of adults with and without intellectual and developmental disabilities in Ontario, Canada. Disabil. Health J. 15, 101174 (2022).","journal-title":"Disabil. Health J."},{"key":"1489_CR14","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1111\/jir.12196","volume":"59","author":"H Uppal","year":"2015","unstructured":"Uppal, H., Chandran, S. & Potluri, R. Risk factors for mortality in Down syndrome. J. Intellect. Disabil. Res 59, 873\u2013881 (2015).","journal-title":"J. Intellect. Disabil. Res"},{"key":"1489_CR15","doi-asserted-by":"crossref","unstructured":"Miller, C. L. Deaths from measles in England and Wales, 1970-83. Br. Med J. (Clin. Res Ed.) 290, 443\u2013444 (1985).","DOI":"10.1136\/bmj.290.6466.443"},{"key":"1489_CR16","doi-asserted-by":"crossref","unstructured":"Ak\u00e7ay, N., Tosun, D. & Bing\u00f6l, \u0130. Is measles particularly hazardous in cases of trisomy 21? J. Pediatr. Infect. Dis. 20, 7 (2025).","DOI":"10.53391\/1305-7707.1037"},{"key":"1489_CR17","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/jpc.13214","volume":"52","author":"C Joffre","year":"2016","unstructured":"Joffre, C. et al. Children with Down syndrome: Clinical course and mortality-associated factors in a French medical paediatric intensive care unit. J. Paediatr. Child Health 52, 595\u2013599 (2016).","journal-title":"J. Paediatr. Child Health"},{"key":"1489_CR18","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jpeds.2020.03.025","volume":"223","author":"DL Langkamp","year":"2020","unstructured":"Langkamp, D. L., Dusseau, A. & Brown, M. F. Vaccine hesitancy and low immunization rates in children with down Syndrome. J. Pediatr. 223, 64\u201367.e2 (2020).","journal-title":"J. Pediatr."},{"key":"1489_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/ajmg.a.11","volume":"179","author":"MA Stanley","year":"2019","unstructured":"Stanley, M. A. et al. Clinical identification of feeding and swallowing disorders in 0-6 month old infants with Down syndrome. Am. J. Med. Genet. A 179, 177\u2013182 (2019).","journal-title":"Am. J. Med. Genet. A"},{"key":"1489_CR20","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1002\/ppul.24458","volume":"54","author":"A Jackson","year":"2019","unstructured":"Jackson, A. et al. Associations between age, respiratory comorbidities, and dysphagia in infants with down syndrome. Pediatr. Pulmonol. 54, 1853\u20131859 (2019).","journal-title":"Pediatr. Pulmonol."},{"key":"1489_CR21","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jpeds.2016.08.063","volume":"180","author":"D Bush","year":"2017","unstructured":"Bush, D., Abman, S. H. & Galambos, C. Prominent intrapulmonary bronchopulmonary anastomoses and abnormal lung development in infants and children with Down syndrome. J. Pediatr. 180, 156\u2013162.e1 (2017).","journal-title":"J. Pediatr."},{"key":"1489_CR22","doi-asserted-by":"publisher","first-page":"A1075","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A1075","volume":"211","author":"A Welham","year":"2025","unstructured":"Welham, A. et al. Human airway epithelial cell expression of HMOX1 and hypoxia gene responses are impaired by trisomy 21 at baseline and during RSV infection. Am. J. Respir. Crit. Care Med. 211, A1075\u2013A1075 (2025).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1489_CR23","doi-asserted-by":"publisher","first-page":"1553984","DOI":"10.3389\/fped.2025.1553984","volume":"13","author":"VE Craven","year":"2025","unstructured":"Craven, V. E. et al. Respiratory and airway disorders in children with Down Syndrome: a review of the clinical challenges and management. Front. Pediatr. 13, 1553984 (2025).","journal-title":"Front. Pediatr."},{"key":"1489_CR24","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1002\/gps.930","volume":"18","author":"D Millichap","year":"2003","unstructured":"Millichap, D. et al. Descriptive functional analysis of behavioral excesses shown by adults with Down syndrome and dementia. Int J. Geriatr. Psychiatry 18, 844\u2013854 (2003).","journal-title":"Int J. Geriatr. Psychiatry"},{"key":"1489_CR25","doi-asserted-by":"publisher","first-page":"621","DOI":"10.5014\/ajot.58.6.621","volume":"58","author":"AS Dolva","year":"2004","unstructured":"Dolva, A. S., Coster, W. & Lilja, M. Functional performance in children with Down syndrome. Am. J. Occup. Ther. 58, 621\u2013629 (2004).","journal-title":"Am. J. Occup. Ther."},{"key":"1489_CR26","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.clicom.2025.09.001","volume":"8","author":"T Satnarine","year":"2025","unstructured":"Satnarine, T. et al. Immunologic profiles and infection patterns in patients with down syndrome: a retrospective review. Clin. Immunol. Commun. 8, 54\u201359 (2025).","journal-title":"Clin. Immunol. Commun."},{"key":"1489_CR27","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/imr.13296","volume":"322","author":"M Ramba","year":"2024","unstructured":"Ramba, M. & Bogunovic, D. The immune system in Down syndrome: autoimmunity and severe infections. Immunol. Rev. 322, 300\u2013310 (2024).","journal-title":"Immunol. Rev."},{"key":"1489_CR28","doi-asserted-by":"publisher","first-page":"621440","DOI":"10.3389\/fimmu.2021.621440","volume":"12","author":"T Illouz","year":"2021","unstructured":"Illouz, T. et al. Immune dysregulation and the increased risk of complications and mortality following respiratory tract infections in adults with Down syndrome. Front Immunol. 12, 621440 (2021).","journal-title":"Front Immunol."},{"key":"1489_CR29","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/cei\/uxae048","volume":"217","author":"K Nakashima","year":"2024","unstructured":"Nakashima, K. et al. The immunoreactive signature of monocyte-derived dendritic cells from patients with Down syndrome. Clin. Exp. Immunol. 217, 291\u2013299 (2024).","journal-title":"Clin. Exp. Immunol."},{"key":"1489_CR30","doi-asserted-by":"publisher","first-page":"eabi4888","DOI":"10.1126\/scitranslmed.abi4888","volume":"14","author":"K Lambert","year":"2022","unstructured":"Lambert, K. et al. Deep immune phenotyping reveals similarities between aging, Down syndrome, and autoimmunity. Sci. Transl. Med. 14, eabi4888 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1489_CR31","doi-asserted-by":"crossref","unstructured":"Rachubinski, A. L. et al. JAK inhibition decreases the autoimmune burden in Down syndrome. Elife 13, RP99323 (2024).","DOI":"10.7554\/eLife.99323.3"},{"key":"1489_CR32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.humimm.2009.09.361","volume":"71","author":"RM Nisihara","year":"2010","unstructured":"Nisihara, R. M. et al. Mannan-binding lectin deficiency increases the risk of recurrent infections in children with Down\u2019s syndrome. Hum. Immunol. 71, 63\u201366 (2010).","journal-title":"Hum. Immunol."},{"key":"1489_CR33","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/eji.201445049","volume":"45","author":"R Carsetti","year":"2015","unstructured":"Carsetti, R. et al. Reduced numbers of switched memory B cells with high terminal differentiation potential in Down syndrome. Eur. J. Immunol. 45, 903\u2013914 (2015).","journal-title":"Eur. J. Immunol."},{"key":"1489_CR34","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/j.jaci.2014.07.015","volume":"134","author":"RHJ Verstegen","year":"2014","unstructured":"Verstegen, R. H. J. et al. Defective B-cell memory in patients with Down syndrome. J. Allergy Clin. Immunol. 134, 1346\u20131353.e9 (2014).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1489_CR35","doi-asserted-by":"crossref","unstructured":"Szczawi\u0144ska-Pop\u0142onyk, A., Pop\u0142onyk, N. & Awdi, K. Down syndrome in children: a primary immunodeficiency with immune dysregulation. Children 11,1251 (2024).","DOI":"10.3390\/children11101251"},{"key":"1489_CR36","doi-asserted-by":"publisher","first-page":"840","DOI":"10.3389\/fimmu.2020.00840","volume":"11","author":"Y Dieudonn\u00e9","year":"2020","unstructured":"Dieudonn\u00e9, Y. et al. Immune defect in adults with Down syndrome: insights into a complex issue. Front. Immunol. 11, 840 (2020).","journal-title":"Front. Immunol."},{"key":"1489_CR37","doi-asserted-by":"publisher","first-page":"A7311","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A7311","volume":"211","author":"S Bhattacharya","year":"2025","unstructured":"Bhattacharya, S. et al. Dysregulation of pulmonary immune cells in trisomy 21. Am. J. Respir. Crit. Care Med. 211, A7311\u2013A7311 (2025).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1489_CR38","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jpeds.2010.07.023","volume":"158","author":"KM McDowell","year":"2011","unstructured":"McDowell, K. M. & Craven, D. I. Pulmonary complications of Down syndrome during childhood. J. Pediatr. 158, 319\u2013325 (2011).","journal-title":"J. Pediatr."},{"key":"1489_CR39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fped.2020.00073","volume":"8","author":"D Huggard","year":"2020","unstructured":"Huggard, D., Doherty, D. G. & Molloy, E. J. Immune dysregulation in children with Down syndrome. Front. Pediatr. 8, 73 (2020).","journal-title":"Front. Pediatr."},{"key":"1489_CR40","doi-asserted-by":"crossref","unstructured":"Bull, M. J. et al. Health supervision for children and adolescents with Down syndrome. Pediatrics 149, e2022057010 (2022).","DOI":"10.1542\/peds.2022-057010"},{"key":"1489_CR41","doi-asserted-by":"publisher","first-page":"24231","DOI":"10.1073\/pnas.1908129116","volume":"116","author":"P Araya","year":"2019","unstructured":"Araya, P. et al. Trisomy 21 dysregulates T cell lineages toward an autoimmunity-prone state associated with interferon hyperactivity. Proc. Natl. Acad. Sci. USA 116, 24231\u201324241 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1489_CR42","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3389\/fimmu.2019.00447","volume":"10","author":"GE Marcovecchio","year":"2019","unstructured":"Marcovecchio, G. E. et al. Thymic epithelium abnormalities in DiGeorge and Down syndrome patients contribute to dysregulation in T cell development. Front. Immunol. 10, 447 (2019).","journal-title":"Front. Immunol."},{"key":"1489_CR43","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10875-020-00755-0","volume":"40","author":"G Ottaviano","year":"2020","unstructured":"Ottaviano, G. et al. A prevalent CXCR3(+) phenotype of circulating follicular helper t cells indicates humoral dysregulation in children with Down syndrome. J. Clin. Immunol. 40, 447\u2013455 (2020).","journal-title":"J. Clin. Immunol."},{"key":"1489_CR44","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.3389\/fimmu.2018.02683","volume":"9","author":"C Farroni","year":"2018","unstructured":"Farroni, C. et al. Dysregulated miR-155 and miR-125b are related to impaired B-cell responses in Down syndrome. Front. Immunol. 9, 2683 (2018).","journal-title":"Front. Immunol."},{"key":"1489_CR45","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1182\/blood-2015-11-679902","volume":"127","author":"J Toubiana","year":"2016","unstructured":"Toubiana, J. et al. Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. Blood 127, 3154\u20133164 (2016).","journal-title":"Blood"},{"key":"1489_CR46","doi-asserted-by":"crossref","unstructured":"Valentini, D. et al. Safety and long-term immunogenicity of BNT162b2 vaccine in individuals with Down syndrome. J. Clin. Med. 11, 694 (2022).","DOI":"10.3390\/jcm11030694"},{"key":"1489_CR47","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/j.1536-4801.2004.tb00863.x","volume":"39","author":"CT Ferreira","year":"2004","unstructured":"Ferreira, C. T. et al. Immunogenicity and safety of an inactivated hepatitis A vaccine in children with Down syndrome. J. Pediatr. Gastroenterol. Nutr. 39, 337\u2013340 (2004).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"1489_CR48","doi-asserted-by":"crossref","unstructured":"H\u00fcls, A. et al. COVID-19 vaccination of individuals with Down syndrome-data from the trisomy 21 research society survey on safety, efficacy, and factors associated with the decision to be vaccinated. Vaccines 10, 530 (2022).","DOI":"10.3390\/vaccines10040530"},{"key":"1489_CR49","first-page":"100744","volume":"27","author":"A Musolino","year":"2025","unstructured":"Musolino, A. et al. Antibody response after pneumococcal vaccination in a large cohort of Italian children and adolescents with Down syndrome. Vaccine: X 27, 100744 (2025).","journal-title":"Vaccine: X"},{"key":"1489_CR50","doi-asserted-by":"crossref","unstructured":"Malle, L. et al. Atypical inflammatory syndrome triggered by SARS-CoV-2 in infants with Down syndrome. J. Clin. Immunol. 41, 1457\u20131462 (2021).","DOI":"10.1007\/s10875-021-01078-4"},{"key":"1489_CR51","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1093\/cid\/ciac590","volume":"76","author":"L Esparcia-Pinedo","year":"2023","unstructured":"Esparcia-Pinedo, L. et al. Development of an effective immune response in adults with Down syndrome after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Clin. Infect. Dis. 76, e155\u2013e162 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"1489_CR52","doi-asserted-by":"publisher","first-page":"2583416","DOI":"10.1080\/21645515.2025.2583416","volume":"21","author":"LCM Hensen","year":"2025","unstructured":"Hensen, L. C. M. et al. T-cell responses to SARS-CoV-2 vaccinations in adults with Down syndrome - a prospective cohort study. Hum. Vaccin Immunother. 21, 2583416 (2025).","journal-title":"Hum. Vaccin Immunother."},{"key":"1489_CR53","doi-asserted-by":"publisher","first-page":"1155.e1","DOI":"10.1016\/j.cmi.2022.04.008","volume":"28","author":"M Sali","year":"2022","unstructured":"Sali, M. et al. SARS-CoV-2 vaccine humoral response in adults with Down syndrome. Clin. Microbiol. Infect. 28, 1155.e1\u20131155.e4 (2022).","journal-title":"Clin. Microbiol. Infect."},{"key":"1489_CR54","doi-asserted-by":"publisher","first-page":"6689","DOI":"10.1016\/j.vaccine.2015.10.083","volume":"33","author":"D Valentini","year":"2015","unstructured":"Valentini, D. et al. Generation of switched memory B cells in response to vaccination in Down syndrome children and their siblings. Vaccine 33, 6689\u20136696 (2015).","journal-title":"Vaccine"},{"key":"1489_CR55","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-012-0340-5","volume":"15","author":"M Forgey","year":"2013","unstructured":"Forgey, M. & Bursch, B. Assessment and management of pediatric iatrogenic medical trauma. Curr. Psychiatry Rep. 15, 340 (2013).","journal-title":"Curr. Psychiatry Rep."},{"key":"1489_CR56","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1111\/jar.12607","volume":"32","author":"NM Neil","year":"2019","unstructured":"Neil, N. M. & Jones, E. A. Effects of intervention intensity on skill acquisition and task persistence in children with Down syndrome. J. Appl. Res. Intellect. Disabil. 32, 1163\u20131175 (2019).","journal-title":"J. Appl. Res. Intellect. Disabil."},{"key":"1489_CR57","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10864-014-9208-6","volume":"24","author":"N Neil","year":"2015","unstructured":"Neil, N. & Jones, E. A. Studying treatment intensity: lessons from two preliminary studies. J. Behav. Educ. 24, 51\u201373 (2015).","journal-title":"J. Behav. Educ."},{"key":"1489_CR58","doi-asserted-by":"publisher","first-page":"889","DOI":"10.15585\/mmwr.mm6433a1","volume":"64","author":"HA Hill","year":"2015","unstructured":"Hill, H. A. et al. National, state, and selected local area vaccination coverage among children aged 19-35 months - United States, 2014. MMWR Morb. Mortal. Wkly. Rep. 64, 889\u2013896 (2015).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"1489_CR59","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1177\/17446295231177787","volume":"28","author":"S Batbold","year":"2024","unstructured":"Batbold, S. et al. Views of parents of children with Down syndrome on Alzheimer\u2019s disease vaccination. J. Intellect. Disabil. 28, 759\u2013772 (2024).","journal-title":"J. Intellect. Disabil."},{"key":"1489_CR60","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1080\/02739615.2020.1740883","volume":"49","author":"LC Sahni","year":"2020","unstructured":"Sahni, L. C. et al. Vaccine hesitancy and illness perceptions: comparing parents of children with autism spectrum disorder to other parent groups. Child Health Care 49, 385\u2013402 (2020).","journal-title":"Child Health Care"},{"key":"1489_CR61","unstructured":"Pediatrics, A.A.o. Talking with Vaccine Hesitant Parents. 2025 [cited 2025 Dec. 4]; Available from: https:\/\/www.aap.org\/en\/patient-care\/immunizations\/communicating-with-families-and-promoting-vaccine-confidence\/talking-with-vaccine-hesitant-parents."},{"key":"1489_CR62","doi-asserted-by":"publisher","first-page":"3623","DOI":"10.1016\/j.vaccine.2014.04.085","volume":"32","author":"LE Taylor","year":"2014","unstructured":"Taylor, L. E., Swerdfeger, A. L. & Eslick, G. D. Vaccines are not associated with autism: an evidence-based meta-analysis of case-control and cohort studies. Vaccine 32, 3623\u20133629 (2014).","journal-title":"Vaccine"},{"key":"1489_CR63","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ejpn.2021.12.011","volume":"36","author":"LV Gabis","year":"2022","unstructured":"Gabis, L. V. et al. The myth of vaccination and autism spectrum. Eur. J. Paediatr. Neurol. 36, 151\u2013158 (2022).","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"1489_CR64","doi-asserted-by":"crossref","unstructured":"Pariente, N. & PLoS Biology staff editors. Vaccines work\u2026 and do not cause autism. PLoS Biol. 23, e3003143 (2025).","DOI":"10.1371\/journal.pbio.3003143"},{"key":"1489_CR65","doi-asserted-by":"publisher","first-page":"1250059","DOI":"10.3389\/fped.2023.1250059","volume":"11","author":"D Familiar-Macedo","year":"2023","unstructured":"Familiar-Macedo, D. et al. Serological investigation of vaccine-induced antibodies for measles, rubella, and yellow fever viruses in children vertically exposed to Zika virus or with Down syndrome. Front Pediatr. 11, 1250059 (2023).","journal-title":"Front Pediatr."},{"key":"1489_CR66","first-page":"16","volume":"39","author":"M Oda","year":"1993","unstructured":"Oda, M. et al. A seroimmunological analysis of Down syndrome. Gerontology 39, 16\u201323 (1993).","journal-title":"Gerontology"},{"key":"1489_CR67","first-page":"298","volume":"31","author":"RA Hawkes","year":"1978","unstructured":"Hawkes, R. A., Boughton, C. R. & Schroeter, D. R. The antibody response of institutionalized Down\u2019s syndrome patients to seven microbial antigens. Clin. Exp. Immunol. 31, 298\u2013304 (1978).","journal-title":"Clin. Exp. Immunol."},{"key":"1489_CR68","doi-asserted-by":"publisher","first-page":"102234","DOI":"10.1016\/j.coi.2022.102234","volume":"78","author":"C Britto","year":"2022","unstructured":"Britto, C. & Alter, G. The next frontier in vaccine design: blending immune correlates of protection into rational vaccine design. Curr. Opin. Immunol. 78, 102234 (2022).","journal-title":"Curr. Opin. Immunol."},{"key":"1489_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-024-04889-2","volume":"18","author":"H Hirano","year":"2024","unstructured":"Hirano, H. & Asada, H. Exponential decline, ceiling effect, downregulation, and T-cell response in immunoglobulin G antibody levels after messenger RNA vaccine boosters: a case report. J. Med Case Rep. 18, 631 (2024).","journal-title":"J. Med Case Rep."},{"key":"1489_CR70","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1056\/NEJMoa1315727","volume":"371","author":"CA DiazGranados","year":"2014","unstructured":"DiazGranados, C. A. et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N. Engl. J. Med 371, 635\u2013645 (2014).","journal-title":"N. Engl. J. Med"},{"key":"1489_CR71","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1001\/jama.1994.03520210045030","volume":"272","author":"TM Govaert","year":"1994","unstructured":"Govaert, T. M. et al. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. Jama 272, 1661\u20131665 (1994).","journal-title":"Jama"},{"key":"1489_CR72","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1080\/21645515.2017.1343226","volume":"14","author":"J Smetana","year":"2018","unstructured":"Smetana, J. et al. Influenza vaccination in the elderly. Hum. Vaccin Immunother. 14, 540\u2013549 (2018).","journal-title":"Hum. Vaccin Immunother."},{"key":"1489_CR73","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12979-019-0164-9","volume":"16","author":"SN Crooke","year":"2019","unstructured":"Crooke, S. N. et al. Immunosenescence and human vaccine immune responses. Immun. Ageing 16, 25 (2019).","journal-title":"Immun. Ageing"},{"key":"1489_CR74","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.vaccine.2005.08.105","volume":"24","author":"K Goodwin","year":"2006","unstructured":"Goodwin, K., Viboud, C. & Simonsen, L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 24, 1159\u20131169 (2006).","journal-title":"Vaccine"},{"key":"1489_CR75","doi-asserted-by":"publisher","first-page":"e0185666","DOI":"10.1371\/journal.pone.0185666","volume":"12","author":"IA Nu\u00f1ez","year":"2017","unstructured":"Nu\u00f1ez, I. A. et al. Impact of age and pre-existing influenza immune responses in humans receiving split inactivated influenza vaccine on the induction of the breadth of antibodies to influenza A strains. PLoS ONE 12, e0185666 (2017).","journal-title":"PLoS ONE"},{"key":"1489_CR76","doi-asserted-by":"publisher","first-page":"7188","DOI":"10.1016\/j.vaccine.2015.10.131","volume":"33","author":"CA DiazGranados","year":"2015","unstructured":"DiazGranados, C. A. et al. Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50-64 years of age. Vaccine 33, 7188\u20137193 (2015).","journal-title":"Vaccine"},{"key":"1489_CR77","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1086\/599790","volume":"200","author":"AR Falsey","year":"2009","unstructured":"Falsey, A. R. et al. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J. Infect. Dis. 200, 172\u2013180 (2009).","journal-title":"J. Infect. Dis."},{"key":"1489_CR78","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.vaccine.2016.12.011","volume":"35","author":"A Domnich","year":"2017","unstructured":"Domnich, A. et al. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: a systematic review and meta-analysis. Vaccine 35, 513\u2013520 (2017).","journal-title":"Vaccine"},{"key":"1489_CR79","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1056\/NEJMoa2302099","volume":"389","author":"A Hsiao","year":"2023","unstructured":"Hsiao, A. et al. Recombinant or standard-dose influenza vaccine in adults under 65 years of age. N. Engl. J. Med. 389, 2245\u20132255 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1489_CR80","first-page":"593","volume":"26","author":"F Caldera","year":"2020","unstructured":"Caldera, F. et al. Immunogenicity of high dose influenza vaccine for patients with inflammatory bowel disease on anti-TNF monotherapy: a randomized clinical trial. Inflamm. Bowel Dis. 26, 593\u2013602 (2020).","journal-title":"Inflamm. Bowel Dis."},{"key":"1489_CR81","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1016\/S2665-9913(19)30094-3","volume":"2","author":"I Colmegna","year":"2020","unstructured":"Colmegna, I. et al. Immunogenicity and safety of high-dose versus standard-dose inactivated influenza vaccine in rheumatoid arthritis patients: a randomised, double-blind, active-comparator trial. Lancet Rheumatol. 2, e14\u2013e23 (2020).","journal-title":"Lancet Rheumatol."},{"key":"1489_CR82","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1093\/cid\/cix1082","volume":"66","author":"Y Natori","year":"2018","unstructured":"Natori, Y. et al. A double-blind, randomized trial of high-dose vs standard-dose influenza vaccine in adult solid-organ transplant recipients. Clin. Infect. Dis. 66, 1698\u20131704 (2018).","journal-title":"Clin. Infect. Dis."},{"key":"1489_CR83","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.bbmt.2015.12.003","volume":"22","author":"NB Halasa","year":"2016","unstructured":"Halasa, N. B. et al. Randomized double-blind study of the safety and immunogenicity of standard-dose trivalent inactivated influenza vaccine versus high-dose trivalent inactivated influenza vaccine in adult hematopoietic stem cell transplantation patients. Biol. Blood Marrow Transpl. 22, 528\u2013535 (2016).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"1489_CR84","doi-asserted-by":"publisher","first-page":"19","DOI":"10.7326\/0003-4819-158-1-201301010-00005","volume":"158","author":"N McKittrick","year":"2013","unstructured":"McKittrick, N. et al. Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons: a single-center, parallel, randomized trial. Ann. Intern. Med. 158, 19\u201326 (2013).","journal-title":"Ann. Intern. Med."},{"key":"1489_CR85","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1016\/j.vaccine.2016.04.053","volume":"34","author":"H Hakim","year":"2016","unstructured":"Hakim, H. et al. Immunogenicity and safety of high-dose trivalent inactivated influenza vaccine compared to standard-dose vaccine in children and young adults with cancer or HIV infection. Vaccine 34, 3141\u20133148 (2016).","journal-title":"Vaccine"},{"key":"1489_CR86","doi-asserted-by":"crossref","unstructured":"Domnich, A. et al. Immunogenicity measures of influenza vaccines: a study of 1164 registered clinical trials. Vaccines 8, 325 (2020).","DOI":"10.3390\/vaccines8020325"},{"key":"1489_CR87","doi-asserted-by":"crossref","unstructured":"Boikos, C. et al. Effectiveness of the adjuvanted influenza vaccine in older adults at high risk of influenza complications. Vaccines 9, 862 (2021).","DOI":"10.3390\/vaccines9080862"},{"key":"1489_CR88","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.vaccine.2018.11.039","volume":"37","author":"Z Vajo","year":"2019","unstructured":"Vajo, Z. et al. Licensing the first reduced, 6 \u00b5g dose whole virion, aluminum adjuvanted seasonal influenza vaccine - A randomized-controlled multicenter trial. Vaccine 37, 258\u2013264 (2019).","journal-title":"Vaccine"},{"key":"1489_CR89","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/ni.3328","volume":"17","author":"O Sobolev","year":"2016","unstructured":"Sobolev, O. et al. Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events. Nat. Immunol. 17, 204\u2013213 (2016).","journal-title":"Nat. Immunol."},{"key":"1489_CR90","doi-asserted-by":"publisher","first-page":"eado5937","DOI":"10.1126\/sciimmunol.ado5937","volume":"10","author":"E Ben-Akiva","year":"2025","unstructured":"Ben-Akiva, E. et al. Linking vaccine adjuvant mechanisms of action to function. Sci. Immunol. 10, eado5937 (2025).","journal-title":"Sci. Immunol."},{"key":"1489_CR91","doi-asserted-by":"crossref","unstructured":"Broomfield, B. J., et al., Transient inhibition of type I interferon enhances CD8+ T cell stemness and vaccine protection. J. Exp. Med. 222, e20241148 (2025).","DOI":"10.1084\/jem.20241148"},{"key":"1489_CR92","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1093\/rheumatology\/keab879","volume":"61","author":"L Iancovici","year":"2022","unstructured":"Iancovici, L. et al. Rheumatoid arthritis patients treated with Janus kinase inhibitors show reduced humoral immune responses following BNT162b2 vaccination. Rheumatology 61, 3439\u20133447 (2022).","journal-title":"Rheumatology"},{"key":"1489_CR93","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cmet.2016.05.011","volume":"23","author":"N Barzilai","year":"2016","unstructured":"Barzilai, N. et al. Metformin as a tool to target aging. Cell Metab. 23, 1060\u20131065 (2016).","journal-title":"Cell Metab."},{"key":"1489_CR94","doi-asserted-by":"publisher","first-page":"622262","DOI":"10.3389\/fphar.2021.622262","volume":"12","author":"B Bai","year":"2021","unstructured":"Bai, B. & Chen, H. Metformin: a novel weapon against inflammation. Front. Pharm. 12, 622262 (2021).","journal-title":"Front. Pharm."},{"key":"1489_CR95","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1016\/j.vaccine.2017.03.078","volume":"35","author":"A Diaz","year":"2017","unstructured":"Diaz, A. et al. Metformin improves in vivo and in vitro B cell function in individuals with obesity and type 2 diabetes. Vaccine 35, 2694\u20132700 (2017).","journal-title":"Vaccine"},{"key":"1489_CR96","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.2337\/dc22-0482","volume":"45","author":"AA Aslam","year":"2022","unstructured":"Aslam, A. A. et al. Diabetes and obesity in Down syndrome across the lifespan: a retrospective cohort study using U.K. electronic health records. Diab. Care 45, 2892\u20132899 (2022).","journal-title":"Diab. Care"},{"key":"1489_CR97","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/bs.pmbts.2017.12.003","volume":"155","author":"A Catic","year":"2018","unstructured":"Catic, A. Cellular metabolism and aging. Prog. Mol. Biol. Transl. Sci. 155, 85\u2013107 (2018).","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"1489_CR98","doi-asserted-by":"publisher","first-page":"101255","DOI":"10.1016\/j.redox.2019.101255","volume":"26","author":"CNS Breda","year":"2019","unstructured":"Breda, C. N. S. et al. Mitochondria as central hub of the immune system. Redox Biol. 26, 101255 (2019).","journal-title":"Redox Biol."},{"key":"1489_CR99","doi-asserted-by":"publisher","first-page":"268ra179","DOI":"10.1126\/scitranslmed.3009892","volume":"6","author":"JB Mannick","year":"2014","unstructured":"Mannick, J. B. et al. mTOR inhibition improves immune function in the elderly. Sci. Transl. Med. 6, 268ra179 (2014).","journal-title":"Sci. Transl. Med."},{"key":"1489_CR100","doi-asserted-by":"crossref","unstructured":"Mannick, J. B., et al., TORC1 inhibition enhances immune function and reduces infections in the elderly. Sci. Transl. Med. 10, eaaq1564 (2018).","DOI":"10.1126\/scitranslmed.aaq1564"},{"key":"1489_CR101","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/j.celrep.2019.10.038","volume":"29","author":"KA Waugh","year":"2019","unstructured":"Waugh, K. A. et al. Mass cytometry reveals global immune remodeling with multi-lineage hypersensitivity to type I interferon in Down syndrome. Cell Rep. 29, 1893\u20131908.e4 (2019).","journal-title":"Cell Rep."},{"key":"1489_CR102","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1158\/1078-0432.CCR-14-3239","volume":"22","author":"AM Eiden","year":"2016","unstructured":"Eiden, A. M. et al. Molecular pathways: increased susceptibility to infection is a complication of mTOR inhibitor use in cancer therapy. Clin. Cancer Res 22, 277\u2013283 (2016).","journal-title":"Clin. Cancer Res"},{"key":"1489_CR103","doi-asserted-by":"publisher","first-page":"e13525","DOI":"10.1111\/acel.13525","volume":"21","author":"EC Lorenzo","year":"2022","unstructured":"Lorenzo, E. C. et al. Senescence-induced changes in CD4 T cell differentiation can be alleviated by treatment with senolytics. Aging Cell 21, e13525 (2022).","journal-title":"Aging Cell"},{"key":"1489_CR104","doi-asserted-by":"crossref","unstructured":"Camell, C. D. et al. Senolytics reduce coronavirus-related mortality in old mice. Science 373, eabe4832 (2021).","DOI":"10.1093\/geroni\/igab046.951"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01489-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01489-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01489-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:02:44Z","timestamp":1786320164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01489-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":104,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1489"],"URL":"https:\/\/doi.org\/10.1038\/s41541-026-01489-7","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"18 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Author BK has previously acted as a paid consultant for Pfizer, Teraimmune and Fresh Track Therapeutics, but declares no non-financial competing interests. Authors NS and NB have previously acted as paid members of a safety monitoring advisory board for Ionis Pharmaceuticals; they declare no non-financial competing interests. All other authors declare no financial or non-financial competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"158"}}